Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting April 8, 2022
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results Selected for an Oral Presentation at the 2022 AACR Annual Meeting March 11, 2022
Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics July 13, 2021
Bicycle Therapeutics Announces Significant Progress Across Multiple Therapeutic Programs Beyond Oncology March 31, 2021
